MiR-32-5p Influences High Glucose-induced Cardiac Fibroblast Proliferation and Phenotypic Alteration by Inhibiting DUSP1
Overview
Affiliations
Background: The current study aimed to investigate the effects of miR-32-5p on cardiac fibroblasts (CFs) that were induced with high levels of glucose; we also aimed to identify the potential mechanisms involved in the regulation of DUSP1 expression.
Methods: Human CFs were transfected with a miR-32-5p inhibitor or mimic and were treated with a normal concentration or a high concentration of glucose. Flow cytometry analysis was performed to identify cardiac fibroblasts by examining vimentin, fibronectin (FN) and α-actin expression in human CFs. qRT-PCR and western blot assays were performed to confirm the expression of miR-32-5p, DUSP1 and cardiac fibrosis relevant proteins. The proliferation of CFs was assessed by using MTT assay. An immunocytofluorescent staining assay was performed to determine the protein level of α-SMA and to investigate the degree of phenotypic changes in human CFs. The specific relationship between miR-32-5p and DUSP1 was investigated by a dual luciferase reporter assay. Cell apoptosis rates were measured with flow cytometry and the annexin V-FITC and propidine iodide (PI) staining method.
Results: A luciferase reporter assay indicated that miR-32-5p could directly target DUSP1. High glucose levels resulted in the overexpression of miR-32-5p, which downregulated DUSP1 expression. Both the upregulation of miR-32-5p and the downregulation of DUSP1 promoted cell apoptosis, proliferation and phenotypic changes in human CFs.
Conclusions: All findings in this study provide further evidence for the positive effects of miR-32-5p on cell proliferation and the phenotypic changes in CFs by inhibiting DUSP1 expression, and reveal that miR-32-5p could serve as prognostic diagnostic target for cardiac fibrosis.
Saadat S, Noureddini M, Maleki B, Ehtesham N, Farrokhian A, Verdi J Rep Biochem Mol Biol. 2025; 13(2):243-253.
PMID: 39995645 PMC: 11847587. DOI: 10.61186/rbmb.13.2.243.
Emerging roles of non-coding RNAs in fibroblast to myofibroblast transition and fibrotic diseases.
Xing X, Rodeo S Front Pharmacol. 2024; 15:1423045.
PMID: 39114349 PMC: 11303237. DOI: 10.3389/fphar.2024.1423045.
Triply Enhanced Immunotherapy via Dual Glycan Reforming Integrated with Perforation.
Yang Y, Wang Y, Chao Z, Yang Y, Fang Y, Liu Y Adv Sci (Weinh). 2023; 11(2):e2304971.
PMID: 37870206 PMC: 10787084. DOI: 10.1002/advs.202304971.
Wagh V, Nguemo F, Kiseleva Z, Mader R, Hescheler J, Mohl W ESC Heart Fail. 2023; 10(6):3559-3572.
PMID: 37752740 PMC: 10682869. DOI: 10.1002/ehf2.14516.
Song B, Peng Y, Zheng Y, Zhu Y, Liu W, Wang K Cancer Immunol Immunother. 2023; 72(11):3523-3541.
PMID: 37638981 PMC: 10991472. DOI: 10.1007/s00262-023-03504-5.